WO2014110234A1 - Methods of treating developmental and personality disorders - Google Patents
Methods of treating developmental and personality disorders Download PDFInfo
- Publication number
- WO2014110234A1 WO2014110234A1 PCT/US2014/010837 US2014010837W WO2014110234A1 WO 2014110234 A1 WO2014110234 A1 WO 2014110234A1 US 2014010837 W US2014010837 W US 2014010837W WO 2014110234 A1 WO2014110234 A1 WO 2014110234A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- inositol
- scyllo
- subject
- effective amount
- social withdrawal
- Prior art date
Links
- 208000022821 personality disease Diseases 0.000 title claims abstract description 34
- 238000000034 method Methods 0.000 title claims description 42
- 208000012239 Developmental disease Diseases 0.000 title description 2
- CDAISMWEOUEBRE-UHFFFAOYSA-N scyllo-inosotol Natural products OC1C(O)C(O)C(O)C(O)C1O CDAISMWEOUEBRE-UHFFFAOYSA-N 0.000 claims abstract description 79
- CDAISMWEOUEBRE-CDRYSYESSA-N scyllo-inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O CDAISMWEOUEBRE-CDRYSYESSA-N 0.000 claims abstract description 78
- 206010041243 Social avoidant behaviour Diseases 0.000 claims abstract description 34
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 6
- 241001465754 Metazoa Species 0.000 claims description 33
- 208000029560 autism spectrum disease Diseases 0.000 claims description 20
- 229960000367 inositol Drugs 0.000 claims description 14
- 239000003814 drug Substances 0.000 claims description 12
- 208000001914 Fragile X syndrome Diseases 0.000 claims description 10
- 208000036640 Asperger disease Diseases 0.000 claims description 5
- 201000006062 Asperger syndrome Diseases 0.000 claims description 5
- SQUHHTBVTRBESD-UHFFFAOYSA-N Hexa-Ac-myo-Inositol Natural products CC(=O)OC1C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C(OC(C)=O)C1OC(C)=O SQUHHTBVTRBESD-UHFFFAOYSA-N 0.000 claims description 5
- 208000006289 Rett Syndrome Diseases 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 101100532699 Drosophila melanogaster scyl gene Proteins 0.000 claims description 4
- CDAISMWEOUEBRE-GPIVLXJGSA-N inositol Chemical compound O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@H](O)[C@@H]1O CDAISMWEOUEBRE-GPIVLXJGSA-N 0.000 claims description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract description 14
- 230000006399 behavior Effects 0.000 description 19
- 241000700159 Rattus Species 0.000 description 18
- 238000012360 testing method Methods 0.000 description 13
- 230000003997 social interaction Effects 0.000 description 12
- 230000000694 effects Effects 0.000 description 11
- 210000004556 brain Anatomy 0.000 description 10
- 150000001875 compounds Chemical class 0.000 description 9
- 208000035475 disorder Diseases 0.000 description 9
- 239000000203 mixture Substances 0.000 description 8
- JTJMJGYZQZDUJJ-UHFFFAOYSA-N phencyclidine Chemical compound C1CCCCN1C1(C=2C=CC=CC=2)CCCCC1 JTJMJGYZQZDUJJ-UHFFFAOYSA-N 0.000 description 8
- 239000003981 vehicle Substances 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 7
- 208000022804 avoidant personality disease Diseases 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 208000030964 dependent personality disease Diseases 0.000 description 6
- 229940079593 drug Drugs 0.000 description 5
- 230000003993 interaction Effects 0.000 description 5
- 208000030459 obsessive-compulsive personality disease Diseases 0.000 description 5
- 108010032606 Fragile X Mental Retardation Protein Proteins 0.000 description 4
- 102000007338 Fragile X Mental Retardation Protein Human genes 0.000 description 4
- 241000124008 Mammalia Species 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 208000030886 Traumatic Brain injury Diseases 0.000 description 4
- 230000003542 behavioural effect Effects 0.000 description 4
- 230000006735 deficit Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 201000006417 multiple sclerosis Diseases 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 208000011580 syndromic disease Diseases 0.000 description 4
- 229940124597 therapeutic agent Drugs 0.000 description 4
- 230000009529 traumatic brain injury Effects 0.000 description 4
- 206010003805 Autism Diseases 0.000 description 3
- 208000020706 Autistic disease Diseases 0.000 description 3
- 206010012289 Dementia Diseases 0.000 description 3
- 229940094659 Dopamine reuptake inhibitor Drugs 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 208000012202 Pervasive developmental disease Diseases 0.000 description 3
- 230000001430 anti-depressive effect Effects 0.000 description 3
- 239000000935 antidepressant agent Substances 0.000 description 3
- 229960004170 clozapine Drugs 0.000 description 3
- QZUDBNBUXVUHMW-UHFFFAOYSA-N clozapine Chemical compound C1CN(C)CCN1C1=NC2=CC(Cl)=CC=C2NC2=CC=CC=C12 QZUDBNBUXVUHMW-UHFFFAOYSA-N 0.000 description 3
- 208000010877 cognitive disease Diseases 0.000 description 3
- 239000000221 dopamine uptake inhibitor Substances 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 239000002767 noradrenalin uptake inhibitor Substances 0.000 description 3
- 229940127221 norepinephrine reuptake inhibitor Drugs 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 150000003905 phosphatidylinositols Chemical class 0.000 description 3
- 208000019901 Anxiety disease Diseases 0.000 description 2
- 208000020925 Bipolar disease Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- 206010041250 Social phobia Diseases 0.000 description 2
- 229940123445 Tricyclic antidepressant Drugs 0.000 description 2
- 239000013543 active substance Substances 0.000 description 2
- 238000000540 analysis of variance Methods 0.000 description 2
- 229940005513 antidepressants Drugs 0.000 description 2
- 208000030963 borderline personality disease Diseases 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 230000001934 delay Effects 0.000 description 2
- 231100000673 dose–response relationship Toxicity 0.000 description 2
- 239000003651 drinking water Substances 0.000 description 2
- 235000020188 drinking water Nutrition 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 230000003370 grooming effect Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000027928 long-term synaptic potentiation Effects 0.000 description 2
- 239000002899 monoamine oxidase inhibitor Substances 0.000 description 2
- 238000010149 post-hoc-test Methods 0.000 description 2
- 230000000069 prophylactic effect Effects 0.000 description 2
- 208000020016 psychiatric disease Diseases 0.000 description 2
- 238000004611 spectroscopical analysis Methods 0.000 description 2
- 238000001228 spectrum Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000003029 tricyclic antidepressant agent Substances 0.000 description 2
- AHOUBRCZNHFOSL-YOEHRIQHSA-N (+)-Casbol Chemical compound C1=CC(F)=CC=C1[C@H]1[C@H](COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-YOEHRIQHSA-N 0.000 description 1
- IGLYMJRIWWIQQE-QUOODJBBSA-N (1S,2R)-2-phenylcyclopropan-1-amine (1R,2S)-2-phenylcyclopropan-1-amine Chemical compound N[C@H]1C[C@@H]1C1=CC=CC=C1.N[C@@H]1C[C@H]1C1=CC=CC=C1 IGLYMJRIWWIQQE-QUOODJBBSA-N 0.000 description 1
- YWPHCCPCQOJSGZ-LLVKDONJSA-N (2r)-2-[(2-ethoxyphenoxy)methyl]morpholine Chemical compound CCOC1=CC=CC=C1OC[C@@H]1OCCNC1 YWPHCCPCQOJSGZ-LLVKDONJSA-N 0.000 description 1
- DIWRORZWFLOCLC-HNNXBMFYSA-N (3s)-7-chloro-5-(2-chlorophenyl)-3-hydroxy-1,3-dihydro-1,4-benzodiazepin-2-one Chemical compound N([C@H](C(NC1=CC=C(Cl)C=C11)=O)O)=C1C1=CC=CC=C1Cl DIWRORZWFLOCLC-HNNXBMFYSA-N 0.000 description 1
- WSEQXVZVJXJVFP-HXUWFJFHSA-N (R)-citalopram Chemical compound C1([C@@]2(C3=CC=C(C=C3CO2)C#N)CCCN(C)C)=CC=C(F)C=C1 WSEQXVZVJXJVFP-HXUWFJFHSA-N 0.000 description 1
- RTHCYVBBDHJXIQ-MRXNPFEDSA-N (R)-fluoxetine Chemical compound O([C@H](CCNC)C=1C=CC=CC=1)C1=CC=C(C(F)(F)F)C=C1 RTHCYVBBDHJXIQ-MRXNPFEDSA-N 0.000 description 1
- ZEUITGRIYCTCEM-KRWDZBQOSA-N (S)-duloxetine Chemical compound C1([C@@H](OC=2C3=CC=CC=C3C=CC=2)CCNC)=CC=CS1 ZEUITGRIYCTCEM-KRWDZBQOSA-N 0.000 description 1
- TZJUVVIWVWFLCD-UHFFFAOYSA-N 1,1-dioxo-2-[4-[4-(2-pyrimidinyl)-1-piperazinyl]butyl]-1,2-benzothiazol-3-one Chemical compound O=S1(=O)C2=CC=CC=C2C(=O)N1CCCCN(CC1)CCN1C1=NC=CC=N1 TZJUVVIWVWFLCD-UHFFFAOYSA-N 0.000 description 1
- XKFPYPQQHFEXRZ-UHFFFAOYSA-N 5-methyl-N'-(phenylmethyl)-3-isoxazolecarbohydrazide Chemical compound O1C(C)=CC(C(=O)NNCC=2C=CC=CC=2)=N1 XKFPYPQQHFEXRZ-UHFFFAOYSA-N 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- GDLIGKIOYRNHDA-UHFFFAOYSA-N Clomipramine Chemical compound C1CC2=CC=C(Cl)C=C2N(CCCN(C)C)C2=CC=CC=C21 GDLIGKIOYRNHDA-UHFFFAOYSA-N 0.000 description 1
- 244000060011 Cocos nucifera Species 0.000 description 1
- 235000013162 Cocos nucifera Nutrition 0.000 description 1
- 208000020401 Depressive disease Diseases 0.000 description 1
- HCYAFALTSJYZDH-UHFFFAOYSA-N Desimpramine Chemical compound C1CC2=CC=CC=C2N(CCCNC)C2=CC=CC=C21 HCYAFALTSJYZDH-UHFFFAOYSA-N 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- WYCLKVQLVUQKNZ-UHFFFAOYSA-N Halazepam Chemical compound N=1CC(=O)N(CC(F)(F)F)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 WYCLKVQLVUQKNZ-UHFFFAOYSA-N 0.000 description 1
- 208000016619 Histrionic personality disease Diseases 0.000 description 1
- 206010020751 Hypersensitivity Diseases 0.000 description 1
- 208000036626 Mental retardation Diseases 0.000 description 1
- 102000010909 Monoamine Oxidase Human genes 0.000 description 1
- 108010062431 Monoamine oxidase Proteins 0.000 description 1
- 229940123685 Monoamine oxidase inhibitor Drugs 0.000 description 1
- 208000027120 Narcissistic personality disease Diseases 0.000 description 1
- 208000009668 Neurobehavioral Manifestations Diseases 0.000 description 1
- 102000002002 Neurokinin-1 Receptors Human genes 0.000 description 1
- 108010040718 Neurokinin-1 Receptors Proteins 0.000 description 1
- PHVGLTMQBUFIQQ-UHFFFAOYSA-N Nortryptiline Chemical compound C1CC2=CC=CC=C2C(=CCCNC)C2=CC=CC=C21 PHVGLTMQBUFIQQ-UHFFFAOYSA-N 0.000 description 1
- AHOUBRCZNHFOSL-UHFFFAOYSA-N Paroxetine hydrochloride Natural products C1=CC(F)=CC=C1C1C(COC=2C=C3OCOC3=CC=2)CNCC1 AHOUBRCZNHFOSL-UHFFFAOYSA-N 0.000 description 1
- RMUCZJUITONUFY-UHFFFAOYSA-N Phenelzine Chemical compound NNCCC1=CC=CC=C1 RMUCZJUITONUFY-UHFFFAOYSA-N 0.000 description 1
- 229920005372 Plexiglas® Polymers 0.000 description 1
- MWQCHHACWWAQLJ-UHFFFAOYSA-N Prazepam Chemical compound O=C1CN=C(C=2C=CC=CC=2)C2=CC(Cl)=CC=C2N1CC1CC1 MWQCHHACWWAQLJ-UHFFFAOYSA-N 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- 208000030988 Schizoid Personality disease Diseases 0.000 description 1
- 206010044688 Trisomy 21 Diseases 0.000 description 1
- 210000001766 X chromosome Anatomy 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000008186 active pharmaceutical agent Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 230000016571 aggressive behavior Effects 0.000 description 1
- 229960004538 alprazolam Drugs 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 229960000836 amitriptyline Drugs 0.000 description 1
- KRMDCWKBEZIMAB-UHFFFAOYSA-N amitriptyline Chemical compound C1CC2=CC=CC=C2C(=CCCN(C)C)C2=CC=CC=C21 KRMDCWKBEZIMAB-UHFFFAOYSA-N 0.000 description 1
- 229960002519 amoxapine Drugs 0.000 description 1
- QWGDMFLQWFTERH-UHFFFAOYSA-N amoxapine Chemical compound C12=CC(Cl)=CC=C2OC2=CC=CC=C2N=C1N1CCNCC1 QWGDMFLQWFTERH-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 208000024823 antisocial personality disease Diseases 0.000 description 1
- 230000036506 anxiety Effects 0.000 description 1
- ATALOFNDEOCMKK-OITMNORJSA-N aprepitant Chemical compound O([C@@H]([C@@H]1C=2C=CC(F)=CC=2)O[C@H](C)C=2C=C(C=C(C=2)C(F)(F)F)C(F)(F)F)CCN1CC1=NNC(=O)N1 ATALOFNDEOCMKK-OITMNORJSA-N 0.000 description 1
- 229960001372 aprepitant Drugs 0.000 description 1
- 230000002238 attenuated effect Effects 0.000 description 1
- 239000003693 atypical antipsychotic agent Substances 0.000 description 1
- 229940127236 atypical antipsychotics Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 230000005978 brain dysfunction Effects 0.000 description 1
- 239000007975 buffered saline Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 229960001058 bupropion Drugs 0.000 description 1
- SNPPWIUOZRMYNY-UHFFFAOYSA-N bupropion Chemical compound CC(C)(C)NC(C)C(=O)C1=CC=CC(Cl)=C1 SNPPWIUOZRMYNY-UHFFFAOYSA-N 0.000 description 1
- QWCRAEMEVRGPNT-UHFFFAOYSA-N buspirone Chemical compound C1C(=O)N(CCCCN2CCN(CC2)C=2N=CC=CN=2)C(=O)CC21CCCC2 QWCRAEMEVRGPNT-UHFFFAOYSA-N 0.000 description 1
- 229960002495 buspirone Drugs 0.000 description 1
- 239000007894 caplet Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 208000024825 childhood disintegrative disease Diseases 0.000 description 1
- 229960004782 chlordiazepoxide Drugs 0.000 description 1
- ANTSCNMPPGJYLG-UHFFFAOYSA-N chlordiazepoxide Chemical compound O=N=1CC(NC)=NC2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 ANTSCNMPPGJYLG-UHFFFAOYSA-N 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229960001653 citalopram Drugs 0.000 description 1
- 230000009194 climbing Effects 0.000 description 1
- 229960004606 clomipramine Drugs 0.000 description 1
- DGBIGWXXNGSACT-UHFFFAOYSA-N clonazepam Chemical compound C12=CC([N+](=O)[O-])=CC=C2NC(=O)CN=C1C1=CC=CC=C1Cl DGBIGWXXNGSACT-UHFFFAOYSA-N 0.000 description 1
- 229960003120 clonazepam Drugs 0.000 description 1
- 229960004362 clorazepate Drugs 0.000 description 1
- XDDJGVMJFWAHJX-UHFFFAOYSA-N clorazepic acid Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(C(=O)O)N=C1C1=CC=CC=C1 XDDJGVMJFWAHJX-UHFFFAOYSA-N 0.000 description 1
- 230000006999 cognitive decline Effects 0.000 description 1
- 230000001149 cognitive effect Effects 0.000 description 1
- 208000013407 communication difficulty Diseases 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 229960003914 desipramine Drugs 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229960003529 diazepam Drugs 0.000 description 1
- AAOVKJBEBIDNHE-UHFFFAOYSA-N diazepam Chemical compound N=1CC(=O)N(C)C2=CC=C(Cl)C=C2C=1C1=CC=CC=C1 AAOVKJBEBIDNHE-UHFFFAOYSA-N 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 208000037765 diseases and disorders Diseases 0.000 description 1
- -1 disintegrates Substances 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 230000002222 downregulating effect Effects 0.000 description 1
- 230000003828 downregulation Effects 0.000 description 1
- 229960005426 doxepin Drugs 0.000 description 1
- ODQWQRRAPPTVAG-GZTJUZNOSA-N doxepin Chemical compound C1OC2=CC=CC=C2C(=C/CCN(C)C)/C2=CC=CC=C21 ODQWQRRAPPTVAG-GZTJUZNOSA-N 0.000 description 1
- 229960002866 duloxetine Drugs 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 239000003623 enhancer Substances 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 229950003678 flesinoxan Drugs 0.000 description 1
- NYSDRDDQELAVKP-SFHVURJKSA-N flesinoxan Chemical compound C([C@@H](O1)CO)OC2=C1C=CC=C2N(CC1)CCN1CCNC(=O)C1=CC=C(F)C=C1 NYSDRDDQELAVKP-SFHVURJKSA-N 0.000 description 1
- 229960002464 fluoxetine Drugs 0.000 description 1
- 229960004038 fluvoxamine Drugs 0.000 description 1
- CJOFXWAVKWHTFT-XSFVSMFZSA-N fluvoxamine Chemical compound COCCCC\C(=N/OCCN)C1=CC=C(C(F)(F)F)C=C1 CJOFXWAVKWHTFT-XSFVSMFZSA-N 0.000 description 1
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 1
- 239000007903 gelatin capsule Substances 0.000 description 1
- 229960000647 gepirone Drugs 0.000 description 1
- QOIGKGMMAGJZNZ-UHFFFAOYSA-N gepirone Chemical compound O=C1CC(C)(C)CC(=O)N1CCCCN1CCN(C=2N=CC=CN=2)CC1 QOIGKGMMAGJZNZ-UHFFFAOYSA-N 0.000 description 1
- 229960002158 halazepam Drugs 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 210000001320 hippocampus Anatomy 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 229960004801 imipramine Drugs 0.000 description 1
- BCGWQEUPMDMJNV-UHFFFAOYSA-N imipramine Chemical compound C1CC2=CC=CC=C2N(CCCN(C)C)C2=CC=CC=C21 BCGWQEUPMDMJNV-UHFFFAOYSA-N 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 229940102223 injectable solution Drugs 0.000 description 1
- 238000012482 interaction analysis Methods 0.000 description 1
- 230000003834 intracellular effect Effects 0.000 description 1
- 229950003599 ipsapirone Drugs 0.000 description 1
- 229960002672 isocarboxazid Drugs 0.000 description 1
- 229960004391 lorazepam Drugs 0.000 description 1
- 239000007937 lozenge Substances 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 208000024714 major depressive disease Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 229960004090 maprotiline Drugs 0.000 description 1
- QSLMDECMDJKHMQ-GSXCWMCISA-N maprotiline Chemical compound C12=CC=CC=C2[C@@]2(CCCNC)C3=CC=CC=C3[C@@H]1CC2 QSLMDECMDJKHMQ-GSXCWMCISA-N 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000002483 medication Methods 0.000 description 1
- 230000003340 mental effect Effects 0.000 description 1
- FJQXCDYVZAHXNS-UHFFFAOYSA-N methadone hydrochloride Chemical compound Cl.C=1C=CC=CC=1C(CC(C)N(C)C)(C(=O)CC)C1=CC=CC=C1 FJQXCDYVZAHXNS-UHFFFAOYSA-N 0.000 description 1
- 229960004644 moclobemide Drugs 0.000 description 1
- YHXISWVBGDMDLQ-UHFFFAOYSA-N moclobemide Chemical compound C1=CC(Cl)=CC=C1C(=O)NCCN1CCOCC1 YHXISWVBGDMDLQ-UHFFFAOYSA-N 0.000 description 1
- 230000036651 mood Effects 0.000 description 1
- 230000035772 mutation Effects 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 229960001800 nefazodone Drugs 0.000 description 1
- VRBKIVRKKCLPHA-UHFFFAOYSA-N nefazodone Chemical compound O=C1N(CCOC=2C=CC=CC=2)C(CC)=NN1CCCN(CC1)CCN1C1=CC=CC(Cl)=C1 VRBKIVRKKCLPHA-UHFFFAOYSA-N 0.000 description 1
- 230000003988 neural development Effects 0.000 description 1
- 230000003557 neuropsychological effect Effects 0.000 description 1
- 230000002474 noradrenergic effect Effects 0.000 description 1
- 229960001158 nortriptyline Drugs 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 229960004535 oxazepam Drugs 0.000 description 1
- ADIMAYPTOBDMTL-UHFFFAOYSA-N oxazepam Chemical compound C12=CC(Cl)=CC=C2NC(=O)C(O)N=C1C1=CC=CC=C1 ADIMAYPTOBDMTL-UHFFFAOYSA-N 0.000 description 1
- 239000006179 pH buffering agent Substances 0.000 description 1
- 208000024817 paranoid personality disease Diseases 0.000 description 1
- 229960002296 paroxetine Drugs 0.000 description 1
- 229950010883 phencyclidine Drugs 0.000 description 1
- 229960000964 phenelzine Drugs 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000004926 polymethyl methacrylate Substances 0.000 description 1
- 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 1
- 229920000053 polysorbate 80 Polymers 0.000 description 1
- 229960004856 prazepam Drugs 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002464 receptor antagonist Substances 0.000 description 1
- 229940044551 receptor antagonist Drugs 0.000 description 1
- 230000003989 repetitive behavior Effects 0.000 description 1
- 208000013406 repetitive behavior Diseases 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 208000012672 seasonal affective disease Diseases 0.000 description 1
- 230000009991 second messenger activation Effects 0.000 description 1
- 229940124834 selective serotonin reuptake inhibitor Drugs 0.000 description 1
- MEZLKOACVSPNER-GFCCVEGCSA-N selegiline Chemical compound C#CCN(C)[C@H](C)CC1=CC=CC=C1 MEZLKOACVSPNER-GFCCVEGCSA-N 0.000 description 1
- 229960003946 selegiline Drugs 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 230000000697 serotonin reuptake Effects 0.000 description 1
- 229960002073 sertraline Drugs 0.000 description 1
- VGKDLMBJGBXTGI-SJCJKPOMSA-N sertraline Chemical compound C1([C@@H]2CC[C@@H](C3=CC=CC=C32)NC)=CC=C(Cl)C(Cl)=C1 VGKDLMBJGBXTGI-SJCJKPOMSA-N 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 238000013222 sprague-dawley male rat Methods 0.000 description 1
- 230000000087 stabilizing effect Effects 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 239000012058 sterile packaged powder Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 230000000946 synaptic effect Effects 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 229940127228 tetracyclic antidepressant Drugs 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 229960003741 tranylcypromine Drugs 0.000 description 1
- 229960003991 trazodone Drugs 0.000 description 1
- PHLBKPHSAVXXEF-UHFFFAOYSA-N trazodone Chemical compound ClC1=CC=CC(N2CCN(CCCN3C(N4C=CC=CC4=N3)=O)CC2)=C1 PHLBKPHSAVXXEF-UHFFFAOYSA-N 0.000 description 1
- 229960002431 trimipramine Drugs 0.000 description 1
- ZSCDBOWYZJWBIY-UHFFFAOYSA-N trimipramine Chemical compound C1CC2=CC=CC=C2N(CC(CN(C)C)C)C2=CC=CC=C21 ZSCDBOWYZJWBIY-UHFFFAOYSA-N 0.000 description 1
- 238000007492 two-way ANOVA Methods 0.000 description 1
- 229960004688 venlafaxine Drugs 0.000 description 1
- PNVNVHUZROJLTJ-UHFFFAOYSA-N venlafaxine Chemical compound C1=CC(OC)=CC=C1C(CN(C)C)C1(O)CCCCC1 PNVNVHUZROJLTJ-UHFFFAOYSA-N 0.000 description 1
- 229960001255 viloxazine Drugs 0.000 description 1
- 230000007279 water homeostasis Effects 0.000 description 1
- 230000003442 weekly effect Effects 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
- A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
Definitions
- the invention relates to methods for treating developmental and personality disorders.
- the Autism spectrum or autistic spectrum describes a range of conditions classified as pervasive developmental disorders in the Diagnostic and Statistical Manual of Mental Disorders (DS ).
- Pervasive developmental disorders include autism, Asperger syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Rett syndrome. These disorders are typically characterized by social deficits, communication difficulties, stereotyped or repetitive behaviors and interests, and in some cases, cognitive delays.
- Fragile X syndrome (FXS), Martin-Bell syndrome, or Escalante's syndrome, is a genetic syndrome that is the most widespread single-gene cause of autism and inherited cause of mental retardation among boys. Fragile X syndrome is associated with the expansion of the CGG trinucleotide repeat affecting the Fragile X mental retardation 1 (FMR1) gene on the X chromosome, resulting in a failure to express the fragile X mental retardation protein (FMRP), which is required for normal neural development. Depending on the length of the CGG repeat, an allele may be classified as normal (unaffected by the syndrome), a premutation (at risk of fragile X associated disorders), or full mutation (usually affected by the syndrome). A definitive diagnosis of fragile X syndrome is made through genetic testing to determine the number of CGG repeats. There is currently no drug treatment that has shown benefit specifically for fragile X syndrome. However, medications are commonly used to treat symptoms of attention deficit and hyperactivity, anxiety, and aggression.
- scyllo-inositol ameliorates, prevents or delays onset or emergence of social withdrawal in animals. Accordingly, in an aspect of the invention, there is provided a method of treating social withdrawal in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the subject. In an aspect, the invention provides a method of treating a personality disorder in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the subject.
- a method for preventing the onset of social withdrawal behavior in a subject comprising administering an effective amount of scyllo-inositol to the animal to prevent onset of social withdrawal behavior in the subject.
- the invention provides a method for preventing the onset of a personality disorder behavior in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the animal to prevent onset of the personality disorder behavior in the subject.
- a method for delaying the onset of social withdrawal behavior in a subject comprising administering an effective amount of scyllo-inositol to the subject to delay onset of the social withdrawal behavior in the subject.
- a method for delaying the onset of a personality disorder behavior in a subject comprising administering an effective amount of scyllo- inositol to the subject to delay onset of the personality disorder behavior in the subject.
- the invention provides scyllo-inositol or a pharmaceutical composition comprising scyllo-inositol for use in treating social withdrawal or in the preparation of a medicament for treating social withdrawal in a subject, in particular an animal.
- the invention provides scyllo-inositol or a pharmaceutical composition comprising scyllo-inositol for use in treating a personality disorder or in the preparation of a medicament for treating a personality disorder in a subject, in particular an animal.
- Figure 1 illustrates the effect of scyllo-inositol (EL D005) on body weight. Data are presented as mean ⁇ SE .
- Figure 2 demonstrates the effect of scyllo-inositoi (ELNDGG5) on PCP- induced disruption of social interaction. Data are presented as mean ⁇ 5EIVL Pound signs (#p ⁇ 0.001) indicate a significant difference from vehicle-vehicle, Asterisks (*p ⁇ 0.05, ***p ⁇ 0,QG1 ) indicate significant differencefrom PCP-vehicle.
- Figures 3a - 3c show the social interaction data for rat pairs in each of the treatment groups. Outliers are highlighted.
- BID or "bid” means twice daily administration, when preceded by a quantity, it means that quantity is administered twice at different times in one day.
- Baseline refers to a patient's physical and/or mental condition and measurements related thereto taken before administration of a study drug is begun.
- LTP long term potentiation and is used as an experimental model of memory formation.
- MRS magnetic resonance spectroscopy as applied in scanning images of the brain and measuring compounds in the brain.
- Scyllo-inositol is one of several endogenous stereoisomers of inositol.
- Myo-inosito! (Ml) which is the major endogenous inositol, plays an important role in osmoregulation and in phosphatidyl-inositol (PI) second messenger signaling, Ml is found at -4-5 mM intracellular concentrations in adult brain, while scyl!o-inositol concentrations are usually ⁇ 1mM.
- Scyllo-inositol unlike Ml, is not thought to be phosphorylated or directly involved in PI signaling. Scyllo-inositol is alternatively referred to as "ELfMDQGS" herein.
- Patentality disorder includes without limitation paranoid personality disorder, schizoid personality disorder, schizotypical personality disorder, antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder, avoidant personality disorder, dependent personality disorder, social phobia, obsessive-compulsive personality disorder and personality disorder not otherwise specified.
- Criteria, including behaviors, for classifying the conditions disclosed herein may be found in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), published by the American Psychiatric Association in May 2013, DSM-IV-TR (American Psychiatric Association 2000), and the International Statistical Classification of Diseases and Related Health Problems 10 th Revision (ICD- 10), published by the World Health Organization (WHO) (http://apps.who.int/classifications/icd10/ browse/2010 /en# V).
- DSM-5 Diagnostic and Statistical Manual of Mental Disorders
- ICD- 10 International Statistical Classification of Diseases and Related Health Problems 10 th Revision
- the personality disorder is a Cluster C personality disorder including avoidant personality disorder or social withdrawal, obsessive-compulsive personality disorder (OCPD), and dependent personality disorder (DPD) in DSM-IV-TR (American Psychiatric Association 2000).
- OCPD obsessive-compulsive personality disorder
- DPD dependent personality disorder
- Social withdrawal refers to an abnormal lack of contact with society for members of social species and is usually involuntary, making it distinct from isolating tendencies or actions consciously undertaken by a person.
- Social withdrawal is sometimes referred to "social isolation” or "avoidant personality disorder”.
- Social withdrawal can be a negative symptom of schizophrenia and autism spectrum disorders such as Rett syndrome, Fragile X syndrome and Asperger's syndrome.
- Social withdrawal may be characterized by one or more of the following behaviors: a pervasive pattern of social inhibition, feelings of inadequacy, inferiority or insecurity, feelings of tension and apprehension, extreme sensitivity to negative evaluation, and avoidance of social interaction.
- An avoidant personality disorder may be selected from one of the following subtypes: phobic, conflicted, hypersensitive or self-deserting. (See, Milton, Theadore. "Personality Subtypes Summary", http://www.millon.net Institute for Advanced Studies in Personology and Psychopathology.)
- Social withdrawal may occur along with other menial health disorders, in particular other personality disorders, including without limitation social phobia, dependent personality disorder or borderline personality disorder.
- subject and “patient” are used interchangeably herein, and refer to an animal including a warm-blooded animal such as a mammal, which is afflicted with or suspected of having, at risk of, or being pre-disposed to a disorder or condition disclosed herein, ammal includes without limitation any members of the Mammalia. In general, the terms refer to a human.
- the methods herein for use on subjects/patients contemplate prophylactic as well as curative use. Typical subjects for treatment include persons susceptible to, suffering from or that have suffered a personality disorder, in particular social withdrawal or an avoidant personality disorder.
- Scyllo inositol has completed phase II clinical studies for the treatment of cognitive symptoms of Alzheimer's Disease.
- the study included neuropsychological assessments using the P! -12 item scale (Cummings et al. 1994, Neurology. 1994;44:2308-14), as well as assessments of scyllo-inositol and Mi brain levels using magnetic resonance spectroscopy (MRS).
- MRS data showed a dose-dependent increase of scyllo-inositol, and unexpectedly a corresponding dose-dependent decrease of Ml levels; these changes are significant but sub-maximal at week 24, and reach maximal levels at about 48 to about 78 weeks.
- the maximal I reduction measured at the 3 studied doses was 44%, 88% and 60% at the 250mg, i OOOmg, and 20Q0mg bid doses, respectively.
- scyllo- inositol is thought to competitively inhibit the active M! uptake by its transporter (Sodium-Sensitive Ml transporter. Wiesinger, 1991 , J Neurochem, 58(5): 1698-704).
- the beneficial effects of scyllo-inositol on neuropsychiatric index outcomes seem to be based, at least in part, on the down-regulation of Ml brain levels.
- MRS MRS measurements in normally aged, MCI and AD. Elevated Ml levels showed the strongest correlations with disease stage as measured by cognitive decline (Ml levels were significantly higher in AD than MCI, and in MCI than in normal aged subjects).
- scyllo-inositol are useful for down-regulating and maintaining more normal (i.e., clinically observed range in non-dementia, non-MCI or non-mild Alzherimer's controls) brain levels of Ml in patients, such as dementia patients or Down's syndrome patients, where Ml is elevated and in bipolar disorder where Ml reduction has been demonstrated to have mood stabilizing therapeutic effects.
- the optimal range of Ml reduction for treating social withdrawal seems to be from about 20 to about 90%, or from about 40% to about 85%, or about 50% to about 80% from baseline.
- the amount of scyllo-inositol administered is the amount which reduces Ml to about 75% from baseline.
- a method of treating a personality disorder in an animal comprising administering an effective amount of scyllo-inositol to the subject.
- a method for preventing the onset of a personality disorder behavior in an animal comprising administering an effective amount of scyllo- inositol to the animal to prevent onset of the personality disorder behavior in the animal.
- a method for delaying the onset of a personality disorder behavior in an animal comprising administering an effective amount of scylio-inositol to the animal to delay onset of the personality disorder behavior in said animal.
- the personality disorder is a Cluster C personality disorder selected from the group consisting of avoidant personality disorder or social withdrawal, obsessive-compulsive personality disorder (OCPD), and dependent personality disorder (DPD).
- a method of treating social withdrawal in an animal comprising administering an effective amount of scylio-inositol to the subject.
- a method for preventing the onset of social withdrawal behavior in an animal comprising administering an effective amount of scy!io-inositol to the animal to prevent onset of social withdrawal behavior in the animal.
- a method for delaying the onset of social withdrawal behavior in an animal comprising administering an effective amount of scylio-inositol to the animal to delay onset of social withdrawal behavior in said animal.
- the subject has a pervasive developmental disorder.
- the subject is an animal, in particular a mammal.
- the mammal is a human.
- the human is a child (ages 4-8).
- the human is a preadolescent (ages 9-12).
- the human is an adolescent (ages 13-19).
- the human is a young adult (ages 20-34).
- social withdrawal is a symptom of schizophrenia.
- the animal does not have the neuropsychiatric disorder of schizophrenia.
- social withdrawal is a symptom of an autism spectrum disorder.
- the autism spectrum disorder is Rett syndrome.
- the autism spectrum disorder is Fragile X syndrome.
- the autism spectrum disorder is Asperger's syndrome.
- the animal does not have an autism spectrum disorder.
- a method for treating an autism spectrum disorder in a subject comprising administering an effective amount of scylio-inositol to the subject.
- the autism spectrum disorder is Rett syndrome.
- the autism spectrum disorder is Fragile X syndrome.
- the autism spectrum disorder is Asperger's syndrome.
- a method for treating multiple sclerosis in a subject comprising administering an effective amount of scylio- inositol to the subject.
- a method for treating cognitive disorders in a subject resulting from multiple sclerosis comprising administering an effective amount of scyl!o-inosito! to the subject.
- a method for treating behavioral disorders in a subject resulting from multiple sclerosis comprising administering an effective amount of scyilo- inositol to the subject,
- a method for treating traumatic brain injury in a subject comprising administering an effective amount of scyllo-inositol to the subject.
- a method for treating cognitive disorders in a subject resulting from traumatic brain injury comprising administering an effective amount of scyl!o-inositol to the subject.
- a method for treating behavioral disorders in a subject resulting from traumatic brain injury comprising administering an effective amount of scyllo-inositol to the subject.
- the treatment period is at least about 12 weeks, at least about 1 week, at least about 2 weeks or at least about 3 weeks, In an embodiment of the invention the treatment period is about 4 weeks. In an embodiment of the invention the treatment period is about 8 weeks. In embodiments of the invention, the treatment period is at least about 12 weeks, at least about 24 weeks, at least about 48 weeks or at least about 78 weeks. In another embodiment of the invention the treatment period is at least about 78 weeks.
- an "effective amount” or “therapeutically effective amount” of scyllo- inositol means the amount or dose of scyllo-inositol that provides the desired treatment or prophylactic effects in a patient, for example, reducing the severity or frequency of occurrence of the diseases and disorders herein.
- An effective amount scyllo-inositol can vary according to factors such as the particular disease or disorder, the age, sex, and weight of the patient.
- a dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation.
- an effective amount of scyllo-inositGl is about 1 mg to about 5000mg. In a particular embodiment, an effective amount of scyllo-inositol is about 10mg to about 20G0mg. In a particular embodiment, an effective amount of scyllo-inositol is about 100mg to about 1500mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 150mg to about 1300mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 2Q0mg to about 1200mg per day.
- an effective amount of scyllo-inosito! is about 250mg to about 1100mg per day. In a particular embodiment, an effective amount of scy!lo-inositol is about 300mg to about 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 500mg to about 1500mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 600mg to about 1300mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 700mg to about 1200mg per day.
- an effective amount of scyllo-inositol is about 800mg to about 1100mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 900mg to about 1100mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 500mg per day.
- an effective amount of scyllo-inositol is 500mg per day. In a particular embodiment, the foregoing amounts of scyllo-inositol are administered once daily. In a particular embodiment, the foregoing amounts of scyllo-inositol are administered twice daily. In a particular embodiment, an effective amount of scyllo-inositol is about 250mg twice daily. In a particular embodiment, an effective amount of scyllo-inositol is 250mg twice daily. In a particular embodiment, an effective amount of scyllo-inositol is about 500mg twice daily. In a particular embodiment, an effective amount of scyllo-inositol is SQOrng twice daily. In another particular embodiment, the foregoing amounts of scyllo-inositol are administered three times daily.
- the methods of the invention also include co-administering other pharmaceutically active compounds prior to, following and contemporaneously with administration of scyllo-inositol.
- scyllo-inositol is coadministered with therapeutic agents for treating neuropsychiatric disorders.
- scyllo-inositol may be co-administered with or more additional therapeutic agents including without limitation anti-depressants.
- An anti-depressant may comprise a monoamine oxidase inhibitor, a Reversible inhibitor of monoamine oxidase A (RIMA), a Dopamine reuptake inhibitor (DART), a Norepinephrine-dopamine reuptake inhibitor, a Norepinephrine reuptake inhibitor (NRI), a Serofonin- norepinephrine reuptake inhibitor (SNRT), a Selective serotonin reuptake enhancer (SSRE), a Tricyclic antidepressant (TCA), a Tetracyclic anti-depressant, an NK1 receptor antagonist, or a Noradrenergic and specific serotonergic antidepressant (NaSSA),
- anti-depressants include, but are not limited to, amitriptyline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, maprotiline, nortriptyline and protript
- scyllo-inositol is administered as a composition comprising the foregoing therapeutic agents.
- the invention provides a pharmaceutical composition for use in treating a personality disorder, in particular social withdrawal, comprising scyllo-inositol and one or more second therapeutic agent.
- compositions comprise one or both active agents in subtherapeutic doses (e.g., amounts that are about 25%, 20%, 15%, 10%, 5%, 2%, 1 % or less than a full dose)
- a composition may be in a form for consumption by a subject such as a pill, tablet, caplet, soft and hard gelatin capsule, lozenge, sachet, cachet, vegicap, liquid drop, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or in a liquid medium) suppository, sterile injectable solution, and/or sterile packaged powder.
- a pharmaceutical composition comprising scyllo-inositol may also comprise a pharmaceutically acceptable carrier, excipient, or vehicle.
- a pharmaceutically acceptable carrier, excipient. or vehicle generally refers to a medium which does not interfere with the effectiveness or activity of an active ingredient and which is not toxic to the hosts to which it is administered,
- a carrier, excipient, or vehicle includes diluents, binders, adhesives, lubricants, disintegrates, bulking agents, wetting or emulsifying agents, pH buffering agents, and miscellaneous materials such as absorbants that may be needed in order to prepare a particular composition. Examples of carriers etc.
- compositions and formulations for use in the present invention may be found in, for example, in Remington: The Science and Practice of Pharmacy, 21 st Ed., 2005; Martindale: The Complete Drug Reference, Sweetman, 2005, London: Pharmaceutical Press; Niazi, Handbook of Pharmaceutical Manufacturing Formulations, 2004, CRC Press; and Gibson, Pharmaceutical Preformuiation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, 2001 , Interpharm Press, which are hereby incorporated by reference herein.
- Scyllo-inositol may be prepared according to various conventional synthetic or semi-synthetic techniques or isolated as a natural product from coconut palm, in a particular embodiment, scyllo-inositol is prepared according to the processes described in WO2005035774 and WO2011100670 the entirety of which are incorporated herein by reference.
- mice Male Sprague Dawley rats ( ⁇ 15Qg) from Harlan (indiana) were group housed in standard rat cages, 23/cage for the study. During the period of acclimation, rats were examined on a regular basis, handled, and weighed to assure adequate health and suitability. Rats were maintained on a 12/12 light/dark cycle with lights on at 7:00 a.m. The room temperature was maintained between 20 and 23°C with a relative humidity maintained between 30% and 70%. Chow and water were provided ad libitum for the duration of the study. Animals were randomly assigned across treatment groups and balanced by body-weight. Animais were not disturbed between test days. Testing was conducted during the light cycle of the animals.
- Phencyclidine (Sigma; Lot # 081 4120V; 2 mg/kg) was dissolved in saline and administered subcutaneously (s.c.) twice daily for 5 days prior to test day.
- Reference compound (Sigma; Lot # 010K1206; Clozapine (2.5 mg/kg) was dissolved in 5% PEG:5% Tween 80 in saline and administered intraperitoneally (i.p.) 30 min prior to test at a dose volume of 1 mL/kg.
- Test compound ELND005 (1 and 10 mg/mL) was dissolved in drinking water. Test compound was prepared fresh weekly and administered for 8 weeks prior to testing.
- Body weight measurements were taken prior to the ELND0Q5 treatment commencement and once a week through the duration of the study. Body weights were taken prior to the test as well. For five days prior to test, rats were injected twice daily with either PCP (2 mg/kg; s.c) or saline (s.c). On day 6 and following a 30 min pre- treatment time, a pair of unfamiliar rats, receiving the same treatment were placed in a white Plexiglas open field arena (24" x 17" x 8") and allowed to interact with each other for 6 minutes. Social interactions ( !
- S1' included: sniffing the other rat; grooming the other rat; climbing over or under or around the other rat; following the other rat; or exploring the ano-genital area of the other rat.
- Passive contact and aggressive contact were not considered a measure of social interaction, The time the rats spent interacting with each other during the 8 min test was recorded by a trained observer. The social interaction chambers were thoroughly cleaned after each 8-minute test session.
Landscapes
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention relates to the use of scyllo-inositol in treating personality disorders, in particular social withdrawal, as well as pharmaceutical compositions comprising effective amounts of scyllo-inositol for treating such disorders.
Description
METHODS OF TREATING DEVELOPMENTAL AMD PERSONALITY DISORDERS
FIELD OF THE INVENTION
The invention relates to methods for treating developmental and personality disorders.
BACKGROUND OF THE INVENTION
[001] Various diseases manifest with behavioral and psychiatric disturbances, such as social withdrawal, including major depressive disorder, postpartum depressive disorder, seasonal affective disorder, bipolar disorder, schizophrenia, dementias, Autism spectrum disorders, multiple sclerosis, and traumatic brain injury,
[002] For example, the Autism spectrum or autistic spectrum describes a range of conditions classified as pervasive developmental disorders in the Diagnostic and Statistical Manual of Mental Disorders (DS ). Pervasive developmental disorders include autism, Asperger syndrome, pervasive developmental disorder not otherwise specified (PDD-NOS), childhood disintegrative disorder, and Rett syndrome. These disorders are typically characterized by social deficits, communication difficulties, stereotyped or repetitive behaviors and interests, and in some cases, cognitive delays.
[003] Fragile X syndrome (FXS), Martin-Bell syndrome, or Escalante's syndrome, is a genetic syndrome that is the most widespread single-gene cause of autism and inherited cause of mental retardation among boys. Fragile X syndrome is associated with the expansion of the CGG trinucleotide repeat affecting the Fragile X mental retardation 1 (FMR1) gene on the X chromosome, resulting in a failure to express the fragile X mental retardation protein (FMRP), which is required for normal neural development. Depending on the length of the CGG repeat, an allele may be classified as normal (unaffected by the syndrome), a premutation (at risk of fragile X associated disorders), or full mutation (usually affected by the syndrome). A definitive diagnosis of fragile X syndrome is made through genetic testing to determine the number of CGG repeats. There is currently no drug treatment that has shown benefit specifically for fragile X syndrome. However, medications are commonly used to treat symptoms of attention deficit and hyperactivity, anxiety, and aggression.
[004] It is to be understood that both the foregoing genera! description and the following detail description are exemplary only and are not restrictive of the disclosure, as claimed.
[005] It has been unexpectedly discovered, that scyllo-inositol ameliorates, prevents or delays onset or emergence of social withdrawal in animals. Accordingly, in an aspect of the invention, there is provided a method of treating social withdrawal in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the subject. In an aspect, the invention provides a method of treating a personality disorder in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the subject.
[008] In another aspect of the invention, there is provided a method for preventing the onset of social withdrawal behavior in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the animal to prevent onset of social withdrawal behavior in the subject. In an aspect, the invention provides a method for preventing the onset of a personality disorder behavior in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the animal to prevent onset of the personality disorder behavior in the subject.
[007] in another aspect of the invention, there is provided a method for delaying the onset of social withdrawal behavior in a subject, in particular an animal, comprising administering an effective amount of scyllo-inositol to the subject to delay onset of the social withdrawal behavior in the subject. In an aspect of the invention, there is provided a method for delaying the onset of a personality disorder behavior in a subject, in particular an animal, comprising administering an effective amount of scyllo- inositol to the subject to delay onset of the personality disorder behavior in the subject.
[008] In another aspect, the invention provides scyllo-inositol or a pharmaceutical composition comprising scyllo-inositol for use in treating social withdrawal or in the preparation of a medicament for treating social withdrawal in a subject, in particular an animal. In an aspect, the invention provides scyllo-inositol or a pharmaceutical composition comprising scyllo-inositol for use in treating a personality disorder or in the preparation of a medicament for treating a personality disorder in a subject, in particular an animal.
BRIEF DESCRIPTION
[009] Figure 1 illustrates the effect of scyllo-inositol (EL D005) on body weight. Data are presented as mean ± SE .
[010] Figure 2 demonstrates the effect of scyllo-inositoi (ELNDGG5) on PCP- induced disruption of social interaction. Data are presented as mean ± 5EIVL Pound signs (#p<0.001) indicate a significant difference from vehicle-vehicle, Asterisks (*p<0.05, ***p<0,QG1 ) indicate significant differencefrom PCP-vehicle.
[01 1] Figures 3a - 3c show the social interaction data for rat pairs in each of the treatment groups. Outliers are highlighted.
DETAILED DESCRIPTION OF THE INVENTION!
[012] Particular aspects of the disclosure are described in greater detailed below, The terms, definitions and abbreviations as used in the present application and as clarified or designated herein are intended to represent the meaning within the present disclosure. The patent and scientific literature referred herein is hereby incorporated by reference. The terms and definitions provided herein control, if in conflict with the terms and/or definitions incorporated by reference.
[013] The singular forms "a," "an," and "the" include plural reference unless the context dictates otherwise.
[014] The terms "approximately" and "about" mean to be nearly the same as a referenced number or value. As used herein, the terms "approximately" and "about" should be generally understood to encompass ±10% of a specified amount, frequency or value, With regard to specific values, it should be understood that specific values described herein for subject populations (e.g., the subject of the described clinical trial) represent mean values, unless otherwise indicated. Accordingly, aspects of the present disclosure requiring a particular value in a subject are substantially supported herein by population data in which the relevant value is assessed to be a meaningful delimitation of the subject population.
[015] "BID" or "bid" means twice daily administration, when preceded by a quantity, it means that quantity is administered twice at different times in one day.
[016] "Baseline" refers to a patient's physical and/or mental condition and measurements related thereto taken before administration of a study drug is begun.
[017] "LTP" means long term potentiation and is used as an experimental model of memory formation. Bliss TV, et aL, (1993). "A synaptic model of memory: long-term potentiation in the hippocampus". Nature 381 (6407): 31-39,
[018] "MRS" is magnetic resonance spectroscopy as applied in scanning images of the brain and measuring compounds in the brain.
[019] Scyllo-inositol is one of several endogenous stereoisomers of inositol. Myo-inosito! (Ml), which is the major endogenous inositol, plays an important role in osmoregulation and in phosphatidyl-inositol (PI) second messenger signaling, Ml is found at -4-5 mM intracellular concentrations in adult brain, while scyl!o-inositol concentrations are usually <1mM. Scyllo-inositol, unlike Ml, is not thought to be phosphorylated or directly involved in PI signaling. Scyllo-inositol is alternatively referred to as "ELfMDQGS" herein.
[020] "Personality disorder" includes without limitation paranoid personality disorder, schizoid personality disorder, schizotypical personality disorder, antisocial personality disorder, borderline personality disorder, histrionic personality disorder, narcissistic personality disorder, avoidant personality disorder, dependent personality disorder, social phobia, obsessive-compulsive personality disorder and personality disorder not otherwise specified.
[021] Criteria, including behaviors, for classifying the conditions disclosed herein may be found in the Fifth Edition of the Diagnostic and Statistical Manual of Mental Disorders (DSM-5), published by the American Psychiatric Association in May 2013, DSM-IV-TR (American Psychiatric Association 2000), and the International Statistical Classification of Diseases and Related Health Problems 10th Revision (ICD- 10), published by the World Health Organization (WHO) (http://apps.who.int/classifications/icd10/ browse/2010 /en# V).
[022] In aspects of the invention, the personality disorder is a Cluster C personality disorder including avoidant personality disorder or social withdrawal, obsessive-compulsive personality disorder (OCPD), and dependent personality disorder (DPD) in DSM-IV-TR (American Psychiatric Association 2000).
[023] "Social withdrawal" refers to an abnormal lack of contact with society for members of social species and is usually involuntary, making it distinct from isolating tendencies or actions consciously undertaken by a person. Social withdrawal is sometimes referred to "social isolation" or "avoidant personality disorder". Social withdrawal can be a negative symptom of schizophrenia and autism spectrum disorders such as Rett syndrome, Fragile X syndrome and Asperger's syndrome. Social withdrawal may be characterized by one or more of the following behaviors: a pervasive pattern of social inhibition, feelings of inadequacy, inferiority or insecurity, feelings of tension and apprehension, extreme sensitivity to negative evaluation, and avoidance of social interaction.
[024] An avoidant personality disorder may be selected from one of the following subtypes: phobic, conflicted, hypersensitive or self-deserting. (See, Milton, Theadore. "Personality Subtypes Summary", http://www.millon.net Institute for Advanced Studies in Personology and Psychopathology.)
[025] Social withdrawal may occur along with other menial health disorders, in particular other personality disorders, including without limitation social phobia, dependent personality disorder or borderline personality disorder.
[026] The terms "subject" and "patient" are used interchangeably herein, and refer to an animal including a warm-blooded animal such as a mammal, which is afflicted with or suspected of having, at risk of, or being pre-disposed to a disorder or condition disclosed herein, ammal includes without limitation any members of the Mammalia. In general, the terms refer to a human. The methods herein for use on subjects/patients contemplate prophylactic as well as curative use. Typical subjects for treatment include persons susceptible to, suffering from or that have suffered a personality disorder, in particular social withdrawal or an avoidant personality disorder.
[027] Scyllo inositol has completed phase II clinical studies for the treatment of cognitive symptoms of Alzheimer's Disease. The study included neuropsychological assessments using the P! -12 item scale (Cummings et al. 1994, Neurology. 1994;44:2308-14), as well as assessments of scyllo-inositol and Mi brain levels using magnetic resonance spectroscopy (MRS). MRS data showed a dose-dependent increase of scyllo-inositol, and unexpectedly a corresponding dose-dependent decrease of Ml levels; these changes are significant but sub-maximal at week 24, and reach maximal levels at about 48 to about 78 weeks. The maximal I reduction measured at the 3 studied doses was 44%, 88% and 60% at the 250mg, i OOOmg, and 20Q0mg bid doses, respectively. While not being bound by any particular theory, scyllo- inositol is thought to competitively inhibit the active M! uptake by its transporter (Sodium-Sensitive Ml transporter. Wiesinger, 1991 , J Neurochem, 58(5): 1698-704). The beneficial effects of scyllo-inositol on neuropsychiatric index outcomes seem to be based, at least in part, on the down-regulation of Ml brain levels.
[028] The potential role of increased brain Ml in brain dysfunction is further supported by MRS measurements in normally aged, MCI and AD. Elevated Ml levels showed the strongest correlations with disease stage as measured by cognitive decline (Ml levels were significantly higher in AD than MCI, and in MCI than in normal aged subjects). Thus the methods of lowering brain levels of Ml by use of scyllo-inositol are
useful for down-regulating and maintaining more normal (i.e., clinically observed range in non-dementia, non-MCI or non-mild Alzherimer's controls) brain levels of Ml in patients, such as dementia patients or Down's syndrome patients, where Ml is elevated and in bipolar disorder where Ml reduction has been demonstrated to have mood stabilizing therapeutic effects.
[029] To investigate changes in Ml levels and behavioral outcomes, a series of rodent studies were conducted, Adult male rats were pretreated with scyllo-inositol (1 or 10 mg/mL) or vehicle (drinking water) for 8 weeks prior to the administration of phencydidine (PCP) (2 mg/kg twice daily, 5 days) and tested in a model of social interaction. Unfamiliar rats were placed in an open field arena and their interactions (e.g. sniffing, grooming, ano-gen tal exploration) recorded over time. Subsequently, brain concentrations of scyllo-inositol and Ml were evaluated using a GC/MS/ S method. Analysis of behavior revealed a significant decrease in social interaction time when rats were pretreated with water for 8 weeks and then treated with PCP (p<.01 vs. water/vehicle). In contrast, rats pretreated with scyllo-inositol (1 or 10 mg/mL) before PCP, showed a significant improvement in social interaction times (p<.001 vs. water/PCP). The treatment of rats with scyllo-inositol also resulted in a significant reduction in brain Ml levels (~ 75%). when compared with controls.
[030] The optimal range of Ml reduction for treating social withdrawal seems to be from about 20 to about 90%, or from about 40% to about 85%, or about 50% to about 80% from baseline. In a particular embodiment, the amount of scyllo-inositol administered is the amount which reduces Ml to about 75% from baseline.
[031] The present results indicate that treatment with scyllo-inositol can reduce deficits in social interaction. Accordingly, in an aspect of the invention, there is provided a method of treating a personality disorder in an animal comprising administering an effective amount of scyllo-inositol to the subject. In another aspect of the invention, there is provided a method for preventing the onset of a personality disorder behavior in an animal, comprising administering an effective amount of scyllo- inositol to the animal to prevent onset of the personality disorder behavior in the animal. In another aspect of the invention, there is provided a method for delaying the onset of a personality disorder behavior in an animal, comprising administering an effective amount of scylio-inositol to the animal to delay onset of the personality disorder behavior in said animal. In an aspect, the personality disorder is a Cluster C personality disorder selected from the group consisting of avoidant personality disorder or social
withdrawal, obsessive-compulsive personality disorder (OCPD), and dependent personality disorder (DPD).
[032] In an aspect of the invention, there is provided a method of treating social withdrawal in an animal comprising administering an effective amount of scylio-inositol to the subject. In another aspect of the invention, there is provided a method for preventing the onset of social withdrawal behavior in an animal, comprising administering an effective amount of scy!io-inositol to the animal to prevent onset of social withdrawal behavior in the animal. In another aspect of the invention, there is provided a method for delaying the onset of social withdrawal behavior in an animal, comprising administering an effective amount of scylio-inositol to the animal to delay onset of social withdrawal behavior in said animal. In an embodiment, the subject has a pervasive developmental disorder.
[033] In an embodiment, the subject is an animal, in particular a mammal. In a particular embodiment, the mammal is a human. In an embodiment, the human is a child (ages 4-8). In an embodiment, the human is a preadolescent (ages 9-12). In an embodiment, the human is an adolescent (ages 13-19). In an embodiment, the human is a young adult (ages 20-34).
[034] In a particular embodiment, social withdrawal is a symptom of schizophrenia. In another embodiment, the animal does not have the neuropsychiatric disorder of schizophrenia. In another embodiment, social withdrawal is a symptom of an autism spectrum disorder. In an embodiment, the autism spectrum disorder is Rett syndrome. In another embodiment the autism spectrum disorder is Fragile X syndrome. In another embodiment, the autism spectrum disorder is Asperger's syndrome. In a particular embodiment, the animal does not have an autism spectrum disorder.
[035] In another aspect of the invention, there is provided a method for treating an autism spectrum disorder in a subject comprising administering an effective amount of scylio-inositol to the subject. In a particular embodiment, the autism spectrum disorder is Rett syndrome. In a particular embodiment, the autism spectrum disorder is Fragile X syndrome. In another embodiment, the autism spectrum disorder is Asperger's syndrome.
[038] In another aspect of the invention, there is provided a method for treating multiple sclerosis in a subject comprising administering an effective amount of scylio- inositol to the subject. In another aspect of the invention, there is provided a method
for treating cognitive disorders in a subject resulting from multiple sclerosis comprising administering an effective amount of scyl!o-inosito! to the subject. In another aspect of the invention, there is provided a method for treating behavioral disorders in a subject resulting from multiple sclerosis comprising administering an effective amount of scyilo- inositol to the subject,
[037] In another aspect of the invention, there is provided a method for treating traumatic brain injury in a subject comprising administering an effective amount of scyllo-inositol to the subject. In another aspect of the invention, there s provided a method for treating cognitive disorders in a subject resulting from traumatic brain injury comprising administering an effective amount of scyl!o-inositol to the subject. In another aspect of the invention, there is provided a method for treating behavioral disorders in a subject resulting from traumatic brain injury comprising administering an effective amount of scyllo-inositol to the subject.
[038] In embodiments of the invention, the treatment period is at least about 12 weeks, at least about 1 week, at least about 2 weeks or at least about 3 weeks, In an embodiment of the invention the treatment period is about 4 weeks. In an embodiment of the invention the treatment period is about 8 weeks. In embodiments of the invention, the treatment period is at least about 12 weeks, at least about 24 weeks, at least about 48 weeks or at least about 78 weeks. In another embodiment of the invention the treatment period is at least about 78 weeks.
[039] An "effective amount" or "therapeutically effective amount" of scyllo- inositol means the amount or dose of scyllo-inositol that provides the desired treatment or prophylactic effects in a patient, for example, reducing the severity or frequency of occurrence of the diseases and disorders herein. An effective amount scyllo-inositol can vary according to factors such as the particular disease or disorder, the age, sex, and weight of the patient. A dosage regimen may be adjusted to provide the optimum therapeutic response. For example, several divided doses may be administered daily or the dose may be proportionally reduced as indicated by the exigencies of the therapeutic situation. In a particular embodiment, an effective amount of scyllo-inositGl is about 1 mg to about 5000mg. In a particular embodiment, an effective amount of scyllo-inositol is about 10mg to about 20G0mg. In a particular embodiment, an effective amount of scyllo-inositol is about 100mg to about 1500mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 150mg to about 1300mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about
2Q0mg to about 1200mg per day. In a particular embodiment, an effective amount of scyllo-inosito! is about 250mg to about 1100mg per day. In a particular embodiment, an effective amount of scy!lo-inositol is about 300mg to about 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 500mg to about 1500mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 600mg to about 1300mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 700mg to about 1200mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 800mg to about 1100mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 900mg to about 1100mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is 1000mg per day. In a particular embodiment, an effective amount of scyllo-inositol is about 500mg per day. In a particular embodiment, an effective amount of scyllo-inositol is 500mg per day. In a particular embodiment, the foregoing amounts of scyllo-inositol are administered once daily. In a particular embodiment, the foregoing amounts of scyllo-inositol are administered twice daily. In a particular embodiment, an effective amount of scyllo-inositol is about 250mg twice daily. In a particular embodiment, an effective amount of scyllo-inositol is 250mg twice daily. In a particular embodiment, an effective amount of scyllo-inositol is about 500mg twice daily. In a particular embodiment, an effective amount of scyllo-inositol is SQOrng twice daily. In another particular embodiment, the foregoing amounts of scyllo-inositol are administered three times daily.
[040] The methods of the invention also include co-administering other pharmaceutically active compounds prior to, following and contemporaneously with administration of scyllo-inositol. in a particular embodiment, scyllo-inositol is coadministered with therapeutic agents for treating neuropsychiatric disorders. In a particular embodiment, scyllo-inositol may be co-administered with or more additional therapeutic agents including without limitation anti-depressants. An anti-depressant may comprise a monoamine oxidase inhibitor, a Reversible inhibitor of monoamine oxidase A (RIMA), a Dopamine reuptake inhibitor (DART), a Norepinephrine-dopamine reuptake inhibitor, a Norepinephrine reuptake inhibitor (NRI), a Serofonin- norepinephrine reuptake inhibitor (SNRT), a Selective serotonin reuptake enhancer (SSRE), a Tricyclic antidepressant (TCA), a Tetracyclic anti-depressant, an NK1
receptor antagonist, or a Noradrenergic and specific serotonergic antidepressant (NaSSA), Examples of anti-depressants include, but are not limited to, amitriptyline, clomipramine, doxepin, imipramine and trimipramine; amoxapine, desipramine, maprotiline, nortriptyline and protriptyiine; citalopram, duloxetine, fluoxetine, fluvoxamine, paroxetine and sertraline; isocarboxazid, phenelzine, tranylcypromine and selegiline; moclobemide: venlafaxine; aprepitant; bupropion, nefazodone, trazodone and viloxazine; alprazolam, chlordiazepoxide, clonazepam, chlorazepate, diazepam, halazepam, lorazepam, oxazepam and prazepam; buspirone, flesinoxan, gepirone and ipsapirone, and pharmaceutically acceptable salts thereof,
[041] In an embodiment, scyllo-inositol is administered as a composition comprising the foregoing therapeutic agents. In an embodiment, the invention provides a pharmaceutical composition for use in treating a personality disorder, in particular social withdrawal, comprising scyllo-inositol and one or more second therapeutic agent. In some embodiments, the compositions comprise one or both active agents in subtherapeutic doses (e.g., amounts that are about 25%, 20%, 15%, 10%, 5%, 2%, 1 % or less than a full dose), A composition may be in a form for consumption by a subject such as a pill, tablet, caplet, soft and hard gelatin capsule, lozenge, sachet, cachet, vegicap, liquid drop, elixir, suspension, emulsion, solution, syrup, aerosol (as a solid or in a liquid medium) suppository, sterile injectable solution, and/or sterile packaged powder.
[042] A pharmaceutical composition comprising scyllo-inositol may also comprise a pharmaceutically acceptable carrier, excipient, or vehicle. A pharmaceutically acceptable carrier, excipient. or vehicle generally refers to a medium which does not interfere with the effectiveness or activity of an active ingredient and which is not toxic to the hosts to which it is administered, A carrier, excipient, or vehicle includes diluents, binders, adhesives, lubricants, disintegrates, bulking agents, wetting or emulsifying agents, pH buffering agents, and miscellaneous materials such as absorbants that may be needed in order to prepare a particular composition. Examples of carriers etc. include but are not limited to saline, buffered saline, dextrose, water, glycerol, ethanol, and combinations thereof. The use of such media and agents for an active substance is well known in the art. Compositions and formulations for use in the present invention may be found in, for example, in Remington: The Science and Practice of Pharmacy, 21st Ed., 2005; Martindale: The Complete Drug Reference, Sweetman, 2005, London: Pharmaceutical Press; Niazi, Handbook of Pharmaceutical
Manufacturing Formulations, 2004, CRC Press; and Gibson, Pharmaceutical Preformuiation and Formulation: A Practical Guide from Candidate Drug Selection to Commercial Dosage Form, 2001 , Interpharm Press, which are hereby incorporated by reference herein.
[043] Scyllo-inositol may be prepared according to various conventional synthetic or semi-synthetic techniques or isolated as a natural product from coconut palm, in a particular embodiment, scyllo-inositol is prepared according to the processes described in WO2005035774 and WO2011100670 the entirety of which are incorporated herein by reference.
Animais
Male Sprague Dawley rats (~15Qg) from Harlan (indiana) were group housed in standard rat cages, 23/cage for the study. During the period of acclimation, rats were examined on a regular basis, handled, and weighed to assure adequate health and suitability. Rats were maintained on a 12/12 light/dark cycle with lights on at 7:00 a.m. The room temperature was maintained between 20 and 23°C with a relative humidity maintained between 30% and 70%. Chow and water were provided ad libitum for the duration of the study. Animals were randomly assigned across treatment groups and balanced by body-weight. Animais were not disturbed between test days. Testing was conducted during the light cycle of the animals.
Test Compounds
Challenge compound: Phencyclidine (Sigma; Lot # 081 4120V; 2 mg/kg) was dissolved in saline and administered subcutaneously (s.c.) twice daily for 5 days prior to test day.
Reference compound: (Sigma; Lot # 010K1206; Clozapine (2.5 mg/kg) was dissolved in 5% PEG:5% Tween 80 in saline and administered intraperitoneally (i.p.) 30 min prior to test at a dose volume of 1 mL/kg.
Test compound: ELND005 (1 and 10 mg/mL) was dissolved in drinking water. Test compound was prepared fresh weekly and administered for 8 weeks prior to testing.
Method
Body weight measurements were taken prior to the ELND0Q5 treatment commencement and once a week through the duration of the study. Body weights were taken prior to the test as well. For five days prior to test, rats were injected twice daily with either PCP (2 mg/kg; s.c) or saline (s.c). On day 6 and following a 30 min pre- treatment time, a pair of unfamiliar rats, receiving the same treatment were placed in a white Plexiglas open field arena (24" x 17" x 8") and allowed to interact with each other for 6 minutes. Social interactions (!S1') included: sniffing the other rat; grooming the other rat; climbing over or under or around the other rat; following the other rat; or exploring the ano-genital area of the other rat. Passive contact and aggressive contact were not considered a measure of social interaction, The time the rats spent interacting with each other during the 8 min test was recorded by a trained observer. The social interaction chambers were thoroughly cleaned after each 8-minute test session.
Statistical Analysis
Data were analyzed by analysis of variance (ANOVA) followed by Fisher's post-hoc tests when appropriate. An effect was considered significant if was p<0.05. Outliers defined as two standard deviations above or below the mean in each treatment group were noted in the raw data and excluded in the social interaction analysis. No outliers were excluded for body weights.
Results
The effect of compound ELND005 on body weight is shown in Figure 1 , Two-way ANOVA revealed a significant effect of time and interaction of time x treatment. No overall treatment effect was noted. The effect of compound ELND005 on interaction time is shown in Figure 2. Based on the NPi-12 item assessment, the mean total NPI scores were between 8 and 10 at baseline. This baseline severity is slightly lower than the range reported in many Mild to Moderate AD trials reported in the literature. Oneway ANOVA revealed a significant treatment effect. Post-hoc tests indicated that sub- chronic treatment with PCP significantly decreased social interaction time in rats. The PCP-induced deficit was attenuated by pretreatment with the atypical antipsychotic clozapine and ELND005 at both concentrations (1 and 10 mg/mL). t!eans Table for interaction Time (sec) Effect
Treatment Count I fVfean Std. D©¥. Std, Err.
Water - Vehicle 12 I 90.250 7.008 § 2.023
Water - PCP 12 I 81.187 8.991 I 2.018
Clozapine 2,5 mg/kg - PCP 12 j 79.250 9.507 j 2.744 s EL DQGS 1 mg/ml - PCP 12 1 78.333 8.907 I 2.571
EL D005 10 mg/ml - PCP 12 88.182 8.882 2.075
Fisher's PLSD Interaction Time (sec) Effect Significance Level; 5%
Claims
1. A method of treating social withdrawal in a subject comprising administering an effective amount of scyllo-inositol to the subject.
2. A method of treating a personality disorder in a subject comprising administering an effective amount of scyllo-inositol to the subject.
3. The method of claim 1 or 2, wherein the subject is a human.
4. The meihod of claim 1 , 2 or 3, wherein the effective amount of scy!io-inositoi is from about 1 mg to about 1 ,000mg per day,
5. The method of any one of claims 1 to 4, wherein the scyllo-inositol is administered twice a day.
8. The method of any one of claims 1 to 5, wherein the subject suffers from schizophrenia.
7. The method of any one of claims 1 to 5, wherein the subject suffers from an autism spectrum disorder.
8. The method of claim 7, wherein the autism spectrum disorder is Rett syndrome.
9. The method of claim 7, wherein the autism spectrum disorder is Fragile X syndrome.
10. The method of claim 7, wherein the autism spectrum disorder is Asperger's syndrome.
11. The method of any one of claims 1 to 10, wherein the amount of scyllo- inositol administered is about 250 mg.
12. The method of any one of claims 1 to 11 , wherein the scyllo-inositol is administered twice a day.
13. A method for preventing the onset of social withdrawal behavior in a subject comprising administering an effective amount of scyllo-inositol to the subject to prevent onset of social withdrawal behavior in the subject.
14. A method for delaying the onset of social withdrawal behavior in an animal, comprising administering an effective amount of scyllo-inositol to the subject to delay onset of social withdrawal behavior in the subject.
15. Scyllo-inositol or a pharmaceutical composition comprising scyllo-inositol for use in treating social withdrawal or in the preparation of a medicament for treating social withdrawal in a subject.
16, Scyiio-inositol or a pharmaceutical compositson of claim 15, wherein scyl inositol is present in an amount of about 250 mg.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201361750722P | 2013-01-09 | 2013-01-09 | |
US61/750,722 | 2013-01-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2014110234A1 true WO2014110234A1 (en) | 2014-07-17 |
Family
ID=51167366
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/010837 WO2014110234A1 (en) | 2013-01-09 | 2014-01-09 | Methods of treating developmental and personality disorders |
PCT/US2014/010903 WO2014110277A1 (en) | 2013-01-09 | 2014-01-09 | Methods of treating developmental and personality disorders |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2014/010903 WO2014110277A1 (en) | 2013-01-09 | 2014-01-09 | Methods of treating developmental and personality disorders |
Country Status (1)
Country | Link |
---|---|
WO (2) | WO2014110234A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090326013A1 (en) * | 2007-03-01 | 2009-12-31 | Curt Hendrix | Isomers of inositol niacinate and uses thereof |
US20120116130A1 (en) * | 2010-10-13 | 2012-05-10 | Scott Greenfield | Methods of Synthesis of Scyllitol and Related Compounds |
WO2012173808A1 (en) * | 2011-06-03 | 2012-12-20 | Elan Pharmaceuticals, Inc. | Scyllo-inositol for the treatment of behavioral and psychiatric disorders |
-
2014
- 2014-01-09 WO PCT/US2014/010837 patent/WO2014110234A1/en active Application Filing
- 2014-01-09 WO PCT/US2014/010903 patent/WO2014110277A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20090326013A1 (en) * | 2007-03-01 | 2009-12-31 | Curt Hendrix | Isomers of inositol niacinate and uses thereof |
US20120116130A1 (en) * | 2010-10-13 | 2012-05-10 | Scott Greenfield | Methods of Synthesis of Scyllitol and Related Compounds |
WO2012173808A1 (en) * | 2011-06-03 | 2012-12-20 | Elan Pharmaceuticals, Inc. | Scyllo-inositol for the treatment of behavioral and psychiatric disorders |
Non-Patent Citations (2)
Title |
---|
DE LA FUENTE-SANDOVAL, C. ET AL.: "Higher levels of glutamate in the associative-striatum of subjects with prodromal symptoms of schizophrenia and patients with first-episode psychosis", NEUROPSYCHOPHARMACOLOGY, vol. 36, 2011, pages 1781 - 1791 * |
SHUGHRUE, P. ET AL.: "Chronic treatment with scyllo-inositol reduces brain myo-inositol levels and enhances performance in a rat model of social withdrawal", ALZHEIMER'S & DEMENTIA, vol. 9, no. 4, July 2013 (2013-07-01), pages 157 * |
Also Published As
Publication number | Publication date |
---|---|
WO2014110277A1 (en) | 2014-07-17 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN111201039B (en) | Cannabidiol and 5-HT 2B Use of a combination of receptor agonists amphetamine for the treatment of epilepsy | |
CN111629756A (en) | Use of cannabinoids in the treatment of seizures associated with Lennox-Gastaut syndrome | |
JP2017531667A (en) | Use of cannabinoids in the treatment of hemorrhoids | |
EP3927336A1 (en) | Use of cannabinoids in the treatment of epilepsy | |
JP2021526507A (en) | Compositions and Methods for Treating Sudden Death Induced by Seizures | |
JP6479766B2 (en) | Nalmefene for the treatment of patients with anxiety disorders | |
Tottori et al. | Antidepressant-like responses to the combined sigma and 5-HT1A receptor agonist OPC-14523 | |
Leon et al. | Depression and comorbid medical illness: therapeutic and diagnostic challenges | |
US10195165B2 (en) | Methods of treating Prader-Willi syndrome | |
Müller et al. | Recent clinical advances in pharmacotherapy for levodopa-induced dyskinesia | |
CN111886005B (en) | Use of fluoroethyl normemantine for the prevention and treatment of anxiety | |
PL220308B1 (en) | Use of clenbuterol for autism treatment | |
JP2021519349A (en) | Methods and compositions for the treatment of hallucinations and related pathologies | |
TW200300672A (en) | Treatment of cognitive failure | |
JP2011516604A (en) | Use of (1S, 2R) enantiomers of milnacipran hydrochloride for the prevention and treatment of suicidal behavior in depressed patients | |
US20100303903A1 (en) | Methods of enhancing selective serotonin reuptake inhibitor effects in mammals | |
WO2014110234A1 (en) | Methods of treating developmental and personality disorders | |
CA3221395A1 (en) | Methods and compositions for treating seizure disorders in pediatric patients | |
TWI686192B (en) | Compositions containing tannic acids and uses thereof | |
US20240173339A1 (en) | Cannabinoid formulation for management of depression, anxiety and ptsd, and cannabinoid formulation as a sleep aid | |
JP2018503677A (en) | Compositions and methods for the treatment of neuropsychiatric disorders | |
WO2023215338A1 (en) | Compositions and methods for treating cluster headache | |
WO2023215342A1 (en) | Compositions and methods for treating trigeminal neuralgia | |
Abbasi et al. | Alzheimer’s disease management: current therapy and recent drug development | |
Mohatt et al. | Psychopharmacology of pediatric anxiety disorders |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 14737620 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 14737620 Country of ref document: EP Kind code of ref document: A1 |